340 Medical Management of Cruciate Ligament Rupture
with hip osteoarthritis. J Am Vet Med Assoc
2000;216:1089–1091.
Johnston SA, McLaughlin RM, Budsberg SC. Non-
surgical management of osteoarthritis in dogs. Vet
Clin North Am Small Anim Pract 2008;38:1449–
1470.
Kawabata A. Prostaglandin E2 and pain – an update.
Biol Pharm Bull 2011;34:1170–1073.
Kawahara K, Hohjoh H, Inazumi T, et al.
Prostaglandin E2-induced inflammation: Rel-
evance of prostaglandin E receptors. Biochim
Biophys Acta 2015;1851:414–421.
Kealy RD, Lawler DF, Ballam JM,et al. Evaluation of
the effect of limited food consumption on radio-
graphic evidence of osteoarthritis in dogs. J Am Vet
Med Assoc 2000;217:1678–1680.
Kealy RD, Lawler DF, Ballam JM,et al. Effects of diet
restriction on life span and age-related changes in
dogs. J Am Vet Med Assoc 2002;220:1315–1320.
Kelly GS. The role of glucosamine sulfate and chon-
droitin sulfates in the treatment of degenerative
joint disease. Altern Med Rev 1998;3:27–39.
Knazovicky D, Helgeson ES, Case B,et al. Widespread
somatosensory sensitivity in naturally occurring
canine model of osteoarthritis. Pain 2016;157:1325–
1332
Laflamme DP. Companion Animals Symposium:
Obesity in dogs and cats: What is wrong with being
fat? J Anim Sci 2012;90:1653–1662.
Lascelles BD, McFarland JM, Swann H. Guidelines for
safe and effective use of NSAIDs in dogs. Vet Ther
2005;6:237–251.
Lascelles BDX, Gaynor JS, Smith ES,et al. Amantidine
in a multimodal analgesic regimen for alleviation
of refractory osteoarthritis pain in dogs. J Vet Intern
Med 2008;22:53–59.
Lascelles BD, Knazovicky D, Case B,et al. A canine-
specific anti-nerve growth factor antibody alle-
viates pain and improves mobility and function
in dogs with degenerative joint disease-associated
pain. BMC Vet Res 2015;11:101
Lazar TP, Berry CR, de Haan JJ,et al. Long-term
radiographic comparison of tibial plateau level-
ing osteotomy versus extracapsular stabilization
for cranial cruciate ligament rupture in the dog. Vet
Surg 2005;34:133–141.
Lin CR, Amaya F, Barrett L,et al. Prostaglandin
E2 receptor EP4 contributes to inflammatory
pain hypersensitivity. J Pharmacol Exp Ther
2006;319:1096–1103.
Lippiello L, Woodward J, Karpman R,et al.In vivo
chondroprotection and metabolic synergy of glu-
cosamine and chondroitin sulfate. Clin Orthop Rel
Res 2000;381:229–240.
Lust G, Williams AJ, Burton-Wurster N,et al. Effects
of intramuscular administration of glycosamino-
glycan polysulfates on signs of incipient hip dys-
plasia in growing pups. Am J Vet Res 1992;53:1836–
1843.
Malek S, Sample SJ, Schwartz Z,et al.Effectof
analgesic therapy on clinical outcome measures
in a randomized controlled trial using client-
owned dogs with hip osteoarthirits. BMC Vet Res
2012;8:185.
Mantyh PW, Koltzenburg M, Mendell LM,et al.
Antagonism of nerve growth factor-TrkA signaling
and the relief of pain. Anesthesiology 2011;115:189–
204.
Marincsak R, Toth BI, Czifra G,et al. The analgesic
drug, tramadol, acts as an agonist of the tran-
sient receptor potential vanilloid-1. Anesth Analg
2008;106:1890–1896.
Marshall KW, Manolopoulos V, Mancer K,et al.Ame-
lioration of disease severity by intraarticular hylan
therapy in bilateral canine osteoarthritis. J Orthop
Res 2000;18:416–425.
Marshall WG, Hazewinkel HA, Mullen D,et al.The
effect of weight loss on lameness in obese dogs with
osteoarthritis. Vet Res Commun 2010;34:241–253
Martel-Pelletier J, Raynauld JP, Dorais M,et al.
The levels of the adipokines adipsin and lep-
tin are associated with knee osteoarthritis pro-
gression as assessed by MRI and incidence of
total knee replacement in symptomatic osteoarthri-
tis patients: a post hoc analysis. Rheumatology
(Oxford) 2016;55:680–688.
McCarthy G, O’Donovan J, Jones B,et al. Randomised
double-blind, positive-controlled trial to assess the
efficacy of glucosamine/chondroitin sulfate for
the treatment of dogs with osteoarthritis. Vet J
2007;174:54–61.
McNamara PS, Johnston SA, Todhunter RJ. Slow-
acting disease-modifying osteoarthritis agents. Vet
Clin North Am Small Anim Pract 1997;27:863–
881.
Mehler SJ, May LR, King C, et al. A prospec-
tive, randomized, double blind, placebo-controlled
evaluation of the effects of eicosapentaenoic acid
and docosahexaenoic acid on the clinical signs
and erythrocyte membrane polyunsaturated fatty
acid concentrations in dogs with osteoarthri-
tis. Prostaglandins Leukot Essent Fatty Acids
2016;109:1–7.
Mertens WD, MacLead JN, Fubini L,et al.Polysul-
phated glycosaminoglycans modulate transcrip-
tion of interleukin-1B treated chondrocytes in
monolayer culture. Vet Comp Orthop Traumatol
2003;2:93–98.
Miller WH, Scott DW, Wellington JR. Treatment of
dogs with hip arthritis with a fatty acid supple-
ment. Canine Pract 1992;17:6–8.
Mlacnik E, Bockstahler BA, Muller M,et al. Effects of
caloric restriction and a moderate or intense phys-
iotherapy program for treatment of lameness in
overweightdogs with osteoarthritis. J Am Vet Med
Assoc 2006;229:1756–1760.
Monteiro-Steagall BP, Steagall PV, Lascelles BD. Sys-
tematic review of nonsteroidal anti-inflammatory